|
| 36640958 | Novel oncometabolites and metabolic checkpoints involved in hepatocellular carcinoma development. | J Hepatol | 2023 |
| 37598239 | JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders. | Sci Rep | 2023 |
| 37973811 | Author Correction: JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders. | Sci Rep | 2023 |
| 37061197 | HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia. | J Hepatol | 2023 |
| 37308266 | Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis. | J Pharmacol Exp Ther | 2023 |
| 35194091 | Protein and miRNA profile of circulating extracellular vesicles in patients with primary sclerosing cholangitis. | Sci Rep | 2022 |
| 35716152 | Hepatology Highlights. | Hepatology | 2022 |
| 36279149 | Overcoming Preclinical Safety Obstacles to Discover (<i>S</i>)-<i>N</i>-((1,2,3,5,6,7-Hexahydro-<i>s</i>-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5<i>H</i>-pyrazolo[5,1-<i>b</i>][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor. | J Med Chem | 2022 |
| 36199236 | Complement complex 1 subunit q-mediated hepatic stellate cell activation with connective tissue growth factor elevation is a prognostic factor for survival in rat and human chronic liver diseases. | Hepatol Commun | 2022 |
| 36121757 | Hepatology highlights. | Hepatology | 2022 |
| 35290694 | Hepatology Highlights. | Hepatology | 2022 |
| 32763266 | Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. | J Hepatol | 2021 |
| 33859335 | Surface color spectrophotometry in a murine model of steatosis: an accurate technique with potential applicability in liver procurement. | Lab Invest | 2021 |
| 34777255 | Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. | Front Endocrinol (Lausanne) | 2021 |
| 32923831 | Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH. | Hepatol Commun | 2020 |
| 32818550 | Hypoxia, hypoxia-inducible gene 2 (HIG2)/HILPDA, and intracellular lipolysis in cancer. | Cancer Lett | 2020 |
| 31184999 | Human induced pluripotent stem cell-derived extracellular vesicles reduce hepatic stellate cell activation and liver fibrosis. | JCI Insight | 2019 |
| 29728708 | Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation. | J Mol Med (Berl) | 2018 |
| 27639178 | Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. | Hepatology | 2017 |
| 28249038 | Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis. | PLoS One | 2017 |
| 28615649 | Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis. | Sci Rep | 2017 |
| 26912150 | Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis. | Diabetes Metab J | 2016 |
| 25234945 | Arginase 2 deficiency results in spontaneous steatohepatitis: a novel link between innate immune activation and hepatic de novo lipogenesis. | J Hepatol | 2015 |
| 26783552 | Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-γ. | Cell Mol Gastroenterol Hepatol | 2015 |
| 25909884 | Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation. | Cell Death Differ | 2015 |
| 25849214 | Microparticles release by adipocytes act as "find-me" signals to promote macrophage migration. | PLoS One | 2015 |
| 26020857 | Redox nanoparticles as a novel treatment approach for inflammation and fibrosis associated with nonalcoholic steatohepatitis. | Nanomedicine (Lond) | 2015 |
| 24681344 | Differential regulation of inflammation and apoptosis in Fas-resistant hepatocyte-specific Bid-deficient mice. | J Hepatol | 2014 |
| 25470250 | Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. | PLoS One | 2014 |
| 25251155 | Reduced dietary omega-6 to omega-3 fatty acid ratio and 12/15-lipoxygenase deficiency are protective against chronic high fat diet-induced steatohepatitis. | PLoS One | 2014 |
| 24795036 | Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model. | Dig Dis Sci | 2014 |
| 23600493 | Novel therapeutic targets for nonalcoholic fatty liver disease. | Expert Opin Ther Targets | 2013 |
| 24106341 | Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require Vanin-1 for uptake by endothelial cells. | Sci Signal | 2013 |
| 21959987 | The biphasic nature of hypoxia-induced directional migration of activated human hepatic stellate cells. | J Pathol | 2012 |
| 21145826 | Intracellular reactive oxygen species are required for directional migration of resident and bone marrow-derived hepatic pro-fibrogenic cells. | J Hepatol | 2011 |
| 21563276 | Dissection of the biphasic nature of hypoxia-induced motogenic action in bone marrow-derived human mesenchymal stem cells. | Stem Cells | 2011 |
| 20552556 | Liver fibrosis: a dynamic and potentially reversible process. | Histol Histopathol | 2010 |
| 20818484 | Oxidative stress parameters in paediatric non-alcoholic fatty liver disease. | Int J Mol Med | 2010 |
| 19688698 | Angiogenesis and liver fibrogenesis. | Histol Histopathol | 2009 |
| 18791199 | Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. | Carcinogenesis | 2008 |